title: Reversibility of pamidronate-associated glomerulosclerosis.
abstract: Bisphosphonates such as pamidronate are widely used in the treatment of patients with lytic bony lesions secondary to breast cancer or multiple myeloma, yet they have been associated with deterioration of renal function and histopathological changes in the kidney. There have been recent reports associating the use of pamidronate with the development of the collapsing variant of focal segmental glomerulosclerosis (CFSGS), a rapidly progressive variant of focal segmental glomerulosclerosis that leads to end-stage renal disease. We describe five patients who developed worsening renal function, proteinuria, and nephrotic syndrome while taking pamidronate; three of them had biopsy-proven CFSGS. Pamidronate was discontinued, and a longitudinal follow-up was performed for 10 to 23 months. One patient was able to discontinue hemodialysis, and all patients experienced improvement in renal function and a decrease in proteinuria. In some patients who develop pamidronate-associated CFSGS, renal damage appears to be reversible if the syndrome is recognized early and pamidronate is stopped.
authors.affiliation: Division of Hematology/Oncology, Baylor University Medical Center and Baylor Charles A. Sammons Cancer Center, Dallas, Texas, USA.
authors.forename: Meera
authors.initials: M
authors.lastname: Shreedhara
authors.forename: Andrew Z
authors.initials: AZ
authors.lastname: Fenves
authors.forename: Diana
authors.initials: D
authors.lastname: Benavides
authors.forename: Marvin J
authors.initials: MJ
authors.lastname: Stone